Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET.
Sacchi S, Gugliotta L, Papineschi F, Liberati AM, Rupoli S, Delfini C, Ruggeri M, Cavanna L, Bucalossi A, Benedetti E, Ferrandina C, Vinci G, Morselli M, Torelli G. Sacchi S, et al. Among authors: liberati am. Leukemia. 1998 Mar;12(3):289-94. doi: 10.1038/sj.leu.2400931. Leukemia. 1998. PMID: 9529121 Clinical Trial.
The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases.
Rigacci L, Federico M, Martelli M, Zinzani PL, Cavanna L, Bellesi G, Merli F, Alterini R, Petrucci MT, Tani M, Liberati AM, Vitolo U, Pavone V, Cuneo A, Chisesib T, Brugiatelli M; Intergruppo Italiano Linfomi. Rigacci L, et al. Among authors: liberati am. Leuk Lymphoma. 2003 Nov;44(11):1911-7. doi: 10.1080/1042819031000123564. Leuk Lymphoma. 2003. PMID: 14738142
Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off.
Regazzi MB, Russo D, Iacona I, Sacchi S, Visani G, Lazzarino M, Avvisati G, Pelicci PG, Dastoli G, Grandi C, Spreafico S, Grattoni R, Galieni P, Rupoli S, Maiolo AM, Guerra E, Liberati AM. Regazzi MB, et al. Among authors: liberati am. Clin Drug Investig. 1998;16(1):25-33. doi: 10.2165/00044011-199816010-00004. Clin Drug Investig. 1998. PMID: 18370515
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.
Cortelezzi A, Sciumè M, Liberati AM, Vincenti D, Cuneo A, Reda G, Laurenti L, Zaja F, Marasca R, Chiarenza A, Gritti G, Orsucci L, Storti S, Angelucci E, Cascavilla N, Gobbi M, Mauro FR, Morabito F, Fabris S, Piciocchi A, Vignetti M, Neri A, Rossi D, Giannarelli D, Guarini A, Foà R. Cortelezzi A, et al. Among authors: liberati am. Leukemia. 2014 Mar;28(3):642-8. doi: 10.1038/leu.2013.334. Epub 2013 Nov 13. Leukemia. 2014. PMID: 24220274 Clinical Trial.
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.
Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M. Gay F, et al. Among authors: liberati am. Leukemia. 2017 Aug;31(8):1727-1734. doi: 10.1038/leu.2016.381. Epub 2016 Dec 23. Leukemia. 2017. PMID: 28008174 Free article.
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.
Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, Gaidano G, Patriarca F, Troia R, Fanin R, De Paoli L, Rossi G, Lombardo A, Bertazzoni P, Palumbo A, Sonneveld P, Boccadoro M. Bringhen S, et al. Among authors: liberati am. Leukemia. 2018 Aug;32(8):1803-1807. doi: 10.1038/s41375-018-0024-1. Epub 2018 Jan 30. Leukemia. 2018. PMID: 29479061 Free article. Clinical Trial. No abstract available.
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.
Bringhen S, D'Agostino M, De Paoli L, Montefusco V, Liberati AM, Galieni P, Grammatico S, Muccio VE, Esma F, De Angelis C, Musto P, Ballanti S, Offidani M, Petrucci MT, Gaidano G, Corradini P, Palumbo A, Sonneveld P, Boccadoro M. Bringhen S, et al. Among authors: liberati am. Leukemia. 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16. Leukemia. 2018. PMID: 29263440 Free article. Clinical Trial.
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy.
Cavallo F, Bringhen S, Milone G, Ben-Yehuda D, Nagler A, Calabrese E, Cascavilla N, Montefusco V, Lupo B, Liberati AM, Crippa C, Rossini F, Passera R, Patriarca F, Cafro AM, Omedè P, Carella AM, Peccatori J, Catalano L, Caravita T, Musto P, Petrucci MT, Boccadoro M, Palumbo A. Cavallo F, et al. Among authors: liberati am. Leukemia. 2011 Oct;25(10):1627-31. doi: 10.1038/leu.2011.131. Epub 2011 Jun 3. Leukemia. 2011. PMID: 21637283
207 results